CymitQuimica ha oltre 25 partner, tra i quali spicca il fornitore TargetMol

<p>Kiss2 peptide functions as a positive regulator of reproductive behavior. In COS-7 cells, it binds to its homologous G-protein coupled receptor Kiss2R (GPR54), activating the PKA and PKC signaling pathways through Gas and Gaq proteins. This enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc).</p>

<p>S1H is an analog of human growth hormone (hGH) and acts as an antagonist to the human growth hormone receptor (hGHR). It inhibits the interaction between hGH and hGHR and prevents the phosphorylation of STAT5 in cells treated with hGH.</p>

<p>Neuropeptide Y (human) free acid is the deamidated form of Neuropeptide Y (human, rat, mouse). The amidation of the C-terminal tyrosine in Neuropeptide Y is essential for its function, while the non-amidated form cannot initiate G-protein signaling.</p>

<p>GUB03385 is a long-acting PrRP31 analogue and an effective dual agonist for GPR10 (full agonist, EC50: 0.4 nM) and NPFF2R (partial agonist, EC50: 20 nM), with anti-obesity properties.</p>

<p>OP-145 is a derivative of the antimicrobial peptide LL-37, known for its antibacterial properties against multiple MRSA strains. This compound is applicable in studies on chronic suppurative otitis media.</p>

NOTA-Pep-1L specifically targets the IL13RA2 receptor and is utilized for tumor imaging. Additionally, it is employed in the synthesis and research of radiolabeled conjugates (RDC).

CXCL8 (54-72) is a C-terminal peptide segment of the chemokine CXCL8. This peptide features a long, highly positively charged C-terminal region that interacts with the negative charges on glycosaminoglycans (GAG) to facilitate binding. CXCL8 (54-72) inhibits neutrophil adhesion and migration, as well as adhesion to endothelial cells. It is useful in studying the role of chemokines in inflammatory responses.

155H1 (Compound 11) is a stapled peptide that covalently binds to hMcl1 (172-323) with an IC50 of 18 nM.

GLP-1R/GIPR agonist-1 is a dual receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It mimics the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while suppressing glucagon release, thus lowering blood sugar. This compound is used in research related to metabolic disorders such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

<p>Palm11-PrRP31 is a lipid-modified analog of the endogenous appetite-suppressing neuropeptide (PrRP). It functions as a potent dual agonist for GPR10 (EC50 = 39 pM) and NPFF-R2. By mimicking the natural activity of PrRP, palm11-PrRP31 binds to these receptors to reduce food intake. It has potential applications as an anti-obesity agent and is useful in studying neuropeptide and receptor interactions.</p>

VGN50 is a bioactive molecule that mimics the function of K-Rta, capable of downregulating MYC-mediated gene transcription. VGN50 exhibits antitumor activity.

palm-PrRP31 is a potent dual agonist for GPR10 (EC50=72 pM) and NPFF-R2. It activates downstream signaling pathways by binding to GPR10 and NPFF-R2 receptors, leading to reduced appetite and increased energy expenditure. palm-PrRP31 can be utilized to investigate its mechanism of action in the nervous system, thereby elucidating the complex biological processes involved in the regulation of appetite and energy expenditure.

DP50 is a bifunctional compound containing both an opioid receptor agonist (MOP) and a neuropeptide FF receptor (NPFFR) antagonist. It can be utilized in studies related to analgesia.

<p>RCP168 is a highly selective and potent CXCR4 receptor antagonist with an IC50 of 5 nM. It exhibits superior capacity to inhibit HIV-1 (Human Immunodeficiency Virus type 1) from entering host cells via the CXCR4 receptor compared to natural chemokines. RCP168 suppresses HIV-1 infection by blocking viral binding sites or inducing receptor internalization. It can be utilized in research to study interactions between the CXCR4 receptor and other chemokine receptors.</p>

<p>LDV-FITC TFA is a fluorescent peptide, specifically an FITC-conjugated LDV peptide. This compound binds to the α4β1 integrin with high affinity, displaying a Kd of 0.3 nM in the presence of Mn2+ and 12 nM in its absence, when binding to U937 cells. LDV-FITC TFA is useful for assessing α4β1 integrin affinity.</p>

H2-D b restricted epitopesVSVNucleoprotein (52-59) is a nonapeptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). It binds to MHC class I molecules to present itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs) that recognize and destroy cells expressing the corresponding antigen. This epitope is instrumental in the development of CTL vaccines against the Ebola virus.

AADvac 1 TFA is an active tau peptide vaccine utilized in Alzheimer's disease research. It is formed by conjugating the regulatory peptide 294KDNIKHVPGGGS305, which drives tau oligomerization, with keyhole limpet hemocyanin (KLH), and is formulated with aluminum hydroxide.

RAG8 peptide is an antagonist of protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation and reduces thrombosis without altering hemostasis or increasing bleeding risk. It is applicable in atherosclerosis research.

Globomycin derivative G2A (Compound G2A) is an inhibitor of lipoprotein signal peptidase II (LspA), with an IC50 of 604 nM. It exhibits inhibitory activity against E. coli, P. aeruginosa, and A. baumannii, displaying minimum inhibitory concentrations (MIC) ranging from 12.5 to 32 μg/mL.

<p>The M133 peptide is a coronavirus-specific CD4 T cell epitope. In mice infected with the neurotropic coronavirus (strain JHM of mouse hepatitis virus), the M133 peptide demonstrates immunodominance. It activates CD4 T cells by forming an MHC/peptide complex through binding with MHC II molecules, which is recognized by specific TCRs.</p>

<p>OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.</p>

BCOR(498-514), biotinylated, is the smallest BCL6 binding domain with a KD of 1.32 µM. It can block BCL6-mediated transcriptional repression and induce cell death in lymphoma cells.

<p>AcrAP2 is an antimicrobial peptide found in the venom of the Arabian scorpion (Androctonus crassicauda). It exhibits inhibitory effects on Gram-positive bacteria and yeast while generally showing no activity against Gram-negative bacteria. The cationic-enhanced analogue of AcrAP2 (AcrAP2a) has demonstrated significant antiproliferative effects on certain human cancer cell lines at low concentrations. AcrAP2 holds potential for research in antibacterial and antitumor applications.</p>

CPN-351 (compound 9a) is a pentapeptide that acts as a selective antagonist for human NMUR1, with a pA2 value of 7.35. It exhibits ten times greater antagonistic activity toward human NMUR1 compared to NMUR2. CPN-351 is applicable in inflammation research.

<p>HG1 Toxin is a peptide found in the venom of the scorpion Heterometrus fulvipes, known for its ability to inhibit the potassium channel Kv1.3 (potassium channel Kv1.3). Additionally, HG1 Toxin exhibits trypsin inhibitory activity (Ki=107 nM), making it useful for research into autoimmune diseases.</p>

<p>Cyclic AC253 is an amylin receptor antagonist with an IC50 of 0.3 μM. It offers neuroprotective effects against Aβ toxicity and mitigates Aβ-induced impairments in hippocampal long-term potentiation. Additionally, Cyclic AC253 is capable of penetrating the blood-brain barrier.</p>

Semaglutide (FITC-labeled Semaglutide) is a long-acting analog of human glucagon-like peptide-1, functioning as an agonist of the GLP-1 receptor. It shows potential for research related to type 2 diabetes.

BRC4 peptide, a specific segment of the BRCA2 protein, interacts with the RAD51 protein to assist in repairing broken DNA strands. It is useful in studying DNA repair mechanisms and the development of cancer.

Apo A-I mimetic 5A peptide is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). It facilitates the efflux of cholesterol from inside cells, helping to reduce intracellular cholesterol accumulation. Additionally, Apo A-I mimetic 5A peptide exhibits anti-inflammatory properties, lowering inflammatory markers in blood and tissues. This peptide is used in cardiovascular disease research.

Tet1peptide is a neuron-specific ligand for GT1B ganglioside. It can serve as a ligand for the targeted delivery of functionalized polymers.

VH4127 TFA is a cyclic peptide with a KD of 18 nM for human low-density lipoprotein receptor (hLDLR). It can specifically bind to epidermal growth factor (EGF) LDLR homologous domains in both rodents and humans.

Urocortin II, human acetate, is a selective endogenous peptide agonist of type 2 corticotropin-releasing factor (CRF2) receptors, used to study the role of CRF2 receptors in feeding behavior.

[Gly8]-GLP-1(7-37) acetate is a derivative of GLP-1, where glycine at position 8 is replaced with alanine. [Gly8]-GLP-1(7-37) acetate is also a peptide fragment of the GLP-1 receptor (GLP-1R) agonist, Dulaglutide.

Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic polypeptide targeting CXCR4, known for its significant anticancer properties. It inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and the development of lung metastasis, offering better serum stability and higher CXCR4 affinity (IC50=20 nM) compared to the lead compound. Peptide R54 works synergistically with anti-PD-1 therapy to exhibit antitumor effects in vivo, enhancing granzyme activity and reducing Foxp3 cell infiltration. It is useful for research in colon cancer, ovarian cancer, and melanoma.

ErbB2 peptide is a ligand peptide that targets the E3 ubiquitin ligase associated with PI3K, utilized in synthesizing peptide PROTACs.

Filimelnotide is an agonist of the melanocortin receptor.

Biotin-DEVD-CHO (TFA) is the biotin-conjugated form of the caspase-3 and caspase-7 inhibitor Ac-DEVD-CHO. It can be utilized for affinity purification of active caspase-3, -6, -7, and -8 and is also applicable for in vitro detection of active caspase-3.

Biotin-Gastrin Releasing Peptide, human TFA, is a biotinylated form of the gastrin-releasing peptide (GRP). GRP is a neuropeptide known for its growth-stimulating and tumorigenic properties.

TRAP-14 amide is a protease-activated receptor (PAR) activating peptide and acts as a PAR agonist, with an EC50 of 24 μM. It induces significant platelet aggregation via ADP and MMP-2 dependent pathways and is insensitive to Aspirin. Additionally, TRAP-14 amide effectively increases the surface expression of glycoprotein (GP) Ib and GPIIb/IIIa, as well as the release of ADP.

Knob A peptide GPRPFPAC is a fibrin knob peptide. The PEGylated form of Knob A peptide GPRPFPAC exhibits enhanced anticoagulant activity.

Cys-PKHB1 (Cys-txCD47) is a polypeptide consisting of a cysteine (Cys) residue coupled with PKHB1, which is a CD47 agonist peptide that acts as a thrombospondin-1 peptide mimetic with anti-tumor properties. In breast cancer cells, PKHB1 induces mitochondrial changes, ROS production, intracellular Ca+ accumulation, and calcium-dependent cell death. Additionally, PKHB1 activates the immune system by inducing immunogenic cell death in breast cancer cells.

Lenbelintide is a dual amylin/calcitonin receptor agonist, useful in studies related to obesity.

Z-Val-Val-Nle-diazomethylketone is an inhibitor of cathepsin S (CATS). It significantly suppresses the upregulation of IFNg-induced MHCII molecules, specifically HLA-DR and Ii-p33/35, while increasing the protein level of Ii-p10. This compound can be utilized for research into skin disorders such as psoriasis, atopic dermatitis, and actinic keratosis.

Corza6 TFA is a potent and selective peptide inhibitor of the human voltage-gated proton channel (hHv1). It binds to the external voltage-sensor domain (VSD) loop of hHv1 with a dissociation constant (Kd) of approximately 1 nM under the native hyperpolarized resting membrane potential (RMP) of mammalian cells. Additionally, Corza6 TFA induces sperm capacitation and enables continuous reactive oxygen species (ROS) production in white blood cells (WBC).

Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from the Eps8 protein. It exhibits potent antitumor activity and significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cell proliferation, induces apoptosis, and disrupts the EGFR signaling pathway by inhibiting the expression of downstream signals such as IL-2, TNF-α, and IFN-γ, as well as impeding the Eps8/EGFR interaction. It significantly suppresses tumor growth in HT-29 xenograft models.

Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a transmembrane peptide with significant neuroprotective effects. It alleviates acidotoxic neuronal damage by targeting the ASIC1a-RIPK1 pathway and an auto-inhibition mechanism. This compound effectively safeguards the brain in ischemic stroke mouse models against damage from ischemia and is applicable in research on neurodegenerative diseases, such as Huntington's disease and Parkinson’s disease.

GIP/GLP-1 dual receptor agonist-1 (Compound 4) (sodium) functions as a GIP/GLP-1 receptor agonist. This compound is applicable for research into metabolic disorders and liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Berobenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist.

Zovaglutide is a GLP-1 receptor agonist that is utilized in diabetes research.

L-Phenylalanyl-L-threonine is a dipeptide composed of phenylalanine and threonine, which can be utilized in the synthesis of the cyclic hexapeptide [Banyascyclamide A].

Acmopatide (Compound E-153) is a dual agonist of GIP and GLP-1 receptors and can be utilized in diabetes research.

JKC 302 is an ET-A receptor antagonist that partially inhibits the contraction of tracheal rings in asthmatic rats induced by ET-1.

P9R is an antiviral peptide with broad-spectrum activity against coronaviruses (SARS-CoV-2, MERS-CoV, and SARS-CoV), influenza A H1N1 virus (A(H1N1)pdm09), influenza A H7N9 virus (A(H7N9) virus), and rhinovirus. It binds directly to viruses and inhibits virus-host endosomal acidification. P9R significantly protects mice from infection by influenza A H1N1 virus (A(H1N1)pdm09) without leading to resistant viruses. P9R is applicable in studying pH-dependent respiratory viruses.

Targeting thebacterialsliding clamp peptide 46 TFA is a short peptide that specifically targets the bacterial sliding clamp (SC) and inhibits SC-dependent DNA synthesis.

TE-8105 is a GLP-1 receptor agonist that demonstrates prolonged and enhanced efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

Canine KP-10 is a potent kisspeptin that induces a significant gonadotropin and estradiol response in female dogs during estrus.

Secretin, canine TFA, is an endocrine hormone that stimulates the secretion of pancreatic fluid rich in bicarbonate. Additionally, Secretin, canine TFA, can regulate the primary cell functions and paracellular permeability of gastric monolayer cells through an Src kinase-dependent pathway.

Zenagamtide is an agonist for both glucagon-like peptide-1 (GLP-1) and amylin receptors.

WT1 126-134 peptide is a WT1 polypeptide (Wilms' tumor 1 peptide) (RMFPNAPYL) that activates cytotoxic CD8 T cells to target and destroy WT1+ tumor cells. It can form stable complexes with either H-2Db (murine) or HLA-A0201 (human) molecules. The WT1 126-134 peptide/HLA-A0201 complex exhibits high affinity for humanized monoclonal antibodies (IgG1), with a dissociation constant (Kd) of 0.2 nM. This peptide can be utilized as a T cell vaccine or an antibody target.

G-Pen-GRGDSPCA TFA is an αvβ3 inhibitory RGD peptide. It inhibits neointimal hyperplasia and luminal narrowing following vascular injury and regulates the migration and proliferation of smooth muscle cells. This compound can be utilized in studies related to mechanisms of vascular injury repair.

L803 is a selective somatostatin receptor type 4 (SST4) agonist that can inhibit L-type calcium channel currents (ICa). It holds potential for research into degenerative diseases of retinal ganglion cells (RGC), such as glaucoma.

Pelteobagrin is a broad-spectrum antimicrobial peptide targeting Gram-positive bacteria, Gram-negative bacteria, and fungi (MIC=2-16 μg/mL). It exerts its bactericidal effects by non-competitively disrupting the integrity of cell walls and cytoplasmic membranes. Pelteobagrin holds promise for use in infectious disease research.

GEP44 is a peptide-biased triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), neuropeptide Y1 receptor (Y1-R), and neuropeptide Y2 receptor (Y2-R). It induces GLP-1R-dependent insulin secretion in rat and human islets by offsetting the actions of Y1-R and GLP-1R agonism, controlled by Y1-R antagonists. Additionally, GEP44 enhances glucose uptake in muscle tissue through Y1-R mediation independent of insulin and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 is utilized in studies related to obesity and type 2 diabetes.

c(R3W4V) is an antimicrobial peptide with a stable transmembrane structure. It exhibits inhibitory concentrations (IC50) of 0.27 μM for E. coli, 0.46 μM for S. aureus, and 0.05 μM for B. subtilis.

NN1213 (Peptide 21) is a long-acting human amylin peptide analogue that functions as a selective amylin receptor agonist. It has an EC50 of 0.177 nM for hAMY3R and 0.262 nM for rAMY3R. In both rat and dog models, NN1213 significantly reduces appetite and is utilized in anti-obesity research.

C-telopeptide TFA is a cross-linked peptide of type I collagen, released during bone resorption, and is associated with bone mineral density (BMD).

RK-10 is a peptide that binds to PD-L1. After being conjugated with Cy5 or Biotin, RK-10 can be used to identify PD-L1-expressing tumors through flow cytometry or immunohistochemistry. It is applicable for research in detecting cancers such as non-small cell lung cancer (NSCLC), breast cancer, squamous cell carcinoma, and melanoma.

OVA(250-264) (OVAvac) (OVAp) is an antigenic peptide derived from chicken egg ovalbumin, presented by class I MHC molecule H-2Kb. This peptide, when combined with αMSLN (anti-MSLN antibody), significantly stimulates the production and infiltration of antigen-specific CD8+ T cells, thereby enhancing antitumor effects in an in situ pancreatic cancer mouse model. It is applicable in developing tumor neoantigen vaccines for pancreatic cancer immunotherapy research.

A17 peptide is an Hsp70-targeting peptide. It binds to the ATP-binding domain of Hsp70, specifically inhibiting its chaperone activity. This enhances cellular sensitivity to chemotherapeutic drugs, such as those inducing apoptosis via Cisplatin. A17 peptide is applicable in cancer chemotherapy research, including studies on multiple myeloma.

PLGLAG is a peptide chain that acts as a linker in activatable cell-penetrating peptides (ACPPs). ACPPs containing the PLGLAG linker are primarily sensitive to MMP-2 and MMP-9 in vivo. PLGLAG is applicable in cancer research.

FITC-LC-TAT (47-57) acetate is an FITC-labeled TAT peptide known as a cell-penetrating peptide (CPP). It enhances the yield and solubility of heterologous proteins.

Notch1 (Notchhomolog 1, translocation-associated) encodes a protein that is a member of the NOTCH family. This type I transmembrane protein family is characterized by common structural features, including an extracellular domain made up of multiple epidermal growth factor-like (EGF) repeats and an intracellular domain composed of various types of domains.

(2S,3AS,7aS)-Octahydroindole-2-carboxylic acid is a useful organic compound that has been used in life science related research.

<p>3-[4-(PhenylMethoxy)phenyl]-2-Propenoic acid is primarily used as a reagent and intermediate in organic synthesis.</p>

<p>Compound 15015-57-3, with CAS No. 15015-57-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 15015-57-3 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.</p>

<p>Compound 1769-24-0 is a natural product for research related to life sciences. The catalog number is TPL0186 and the CAS number is 1769-24-0.</p>

Compound 2058-74-4, with CAS No. 2058-74-4, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 2058-74-4 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

4-(Benzo[d]oxazol-2-yl)aniline is a potent antitumor agent that has inhibitory activity against mammary carcinoma cell lines [1].

Compound 19962-37-9, with CAS No. 19962-37-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 19962-37-9 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

<p>Compound 480-68-2, with CAS No. 480-68-2, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 480-68-2 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.</p>

<p>4-Biphenylboronic acid is a boric acid substance widely used in medicine and other fields.</p>

<p>4-Biphenylcarboxylic acid is a polarographic reagent used in pharmaceutical synthesis, with potent antifungal and antibacterial properties.</p>

Compound EN300-20599, with CAS No. 16346-97-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound EN300-20599 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

1,4-Cineole (Isocineole) is a natural, oxygenated monoterpene. 1,4-Cineole can activate both human TRPM8 and human TRPA1.

A-317491 (ABT 202) is a non-nucleotide P2X3 ( Ki: 22 nM) and P2X2/3 receptor (Ki: 9 nM) antagonist, which inhibits calcium flux mediated by the receptors.

A-317491 blocks P2X3 and P2X2/3 receptors, easing inflammatory pain and neuropathy in rats.

740 Y-P (740YPDGFR) is a PI3K activator with cell permeability,binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85. Low-Cost!

<p>740 Y-P(TFA)(1236188-16-1 free base) (740YPDGFR(TFA)) is a potent and cell-permeable activator of PI3K.</p>

740 Y-P acetate (740YPDGFR acetate) is a potent and cell-permeable PI3K activator.740 Y-P acetate tends to bind to GST fusion proteins containing the N- and C-

<p>Albiglutide fragment is a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36).</p>

<p>KO-947 is a potent and specific inhibitor of ERK1/2 kinases.</p>

Cintirorgon (LYC-55716) is a selective, oral agonist of RORγ. Cintirorgon modulates gene expression of RORγ expressing T lymphocyte immune cells.

Cintirorgon (LYC-55716) is an oral RORgamma agonist with immunomodulatory and anticancer effects.

<p>MT-DADMe-ImmA (MTDIA) is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP, Ki: 90 pM).</p>

UCB9608 is a selective and orally active PI4KIIIβ inhibitor (IC50: 11 nM), selective over PI3KC2 α, β, and γ lipid kinases.

Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).

PF-06869206 is an oral selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1, IC50: 380 nM).

<p>AZ3451 is an allosteric antagonist of protease-activated receptor-2 (PAR2, IC50: 23 nM).</p>

<p>BTTAA, a Cu(I)-stabilizing ligand, performs potently with ubiquitin Glu18AzF.</p>

<p>GNE-131 is a potent and specific inhibitor of human sodium channel NaV1.7 (IC50: 3 nM).</p>

<p>PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).</p>

NKP-1339 (IT-139) induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway.

<p>AB-423 is an inhibitor of HBV capsid assembly, and potently inhibits HBV replication (EC50/EC90: 0.08-0.27 μM/0.33-1.32 μM in cells).</p>

<p>6-Amino-5-azacytidine has an inhibitory of the growth of E. coli.</p>

RR6 acts as a selective, reversible, and competitive vanin inhibitor at nanomolar concentration.

<p>AMG 837 calcium hydrate is a potent GPR40 agonist with an EC50 of 13 nM.</p>

<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of &lt;1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>

<p>Capromorelin Tartrate (CP 424391-18) is a potent, orally active growth hormone secretagogue receptor (GHSR) agonist (Ki: 7 nM for hGHS-R1a).</p>

<p>Lorediplon is a novel hypnotic drug acting as a GABAA receptor modulator, differentially active at the α1-subunit, associated with promoting sleep.</p>

3-Hydroxyglutaric acid is one of several metabolites produced when insufficient levels of GCDH are available. It is used as a biomarker of GCDH deficiency.

E7046 is a specific, orally bioavailable EP4 antagonist (IC50: 13.5 nM, Ki: 23.14 nM), exhibiting anti-tumor activities.

MDR-1339 is a blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation.